INMB · Inmune Bio, Inc.
$2.17
+0.09 (+4.33%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's projected operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$60.23M
Shares
27.75M
Inmune Bio, Inc. Earnings Call Transcripts
Every quarterly earnings call for Inmune Bio, Inc. (INMB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$16,000
−$6.84M
'22 Q2
22-08-04
▲600%
$98,000
−$7.72M
'22 Q3
22-11-02
·
$97,000
−$5.83M
'22 Q4
23-03-03
▼76.7%
$38,000
−$6.54M
'23 Q1
23-05-04
▲187.5%
$46,000
−$6.50M
'23 Q2
23-08-08
▼56.1%
$43,000
−$8.56M
'23 Q3
23-11-01
▼71.1%
$28,000
−$8.41M
'23 Q4
24-03-29
▼63.2%
$14,000
−$11.03M
'24 Q1
24-05-13
LATEST
▲257.1%
$50,000
−$9.74M
'25 Q1
25-05-08
Earnings call
FY26 · Q1
2026-03-31
Inmune Bio, Inc. Q1 FY2026 Earnings Call
Positive tone
CORDStrom regulatory filings and MAA submission
RDEB program and branding
XPro program and MINDFuL study
Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-12-31
Inmune Bio, Inc. Q4 FY2025 Earnings Call
Positive tone
CORDStrom RDEB regulatory progress
XPro Alzheimer's program
INKmune prostate cancer program
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Inmune Bio, Inc. Q3 FY2025 Earnings Call
Confident tone
CORDStrom RDEB regulatory progress
Itch reduction / systemic benefit in RDEB
INKmune prostate cancer Phase II
Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Inmune Bio, Inc. Q2 FY2025 Earnings Call
Positive tone
XPro Phase II MINDFuL trial in Alzheimer's
CORDStrom for RDEB regulatory submissions
Strategic partnership exploration
Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Inmune Bio, Inc. Q1 FY2025 Earnings Call
Confident tone
CORDstrom / RDEB program
XPro market opportunity
INKmune prostate cancer program
Revenue
$50,000
▲ 257.1% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inmune Bio, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Inmune Bio, Inc. Q3 FY2024 Earnings Call
Confident tone
XPro ADO2 Phase II Alzheimer’s trial enrollment complete
Ease of delivery / outpatient administration
Treatment-resistant depression Phase II program
Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-02
Inmune Bio, Inc. Q2 FY2024 Earnings Call
Confident tone
INKmune NK cell oncology program
XPro Phase II Alzheimer's trial (AD02)
Treatment-resistant depression program
Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Inmune Bio, Inc. Q1 FY2024 Earnings Call
Positive tone
Alzheimer's Phase II AD02 trial enrollment and design
Regulatory pathway and FDA interaction
XPro long-term safety and patient experience
Revenue
$14,000
▼ 63.2% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Inmune Bio, Inc. Q4 FY2023 Earnings Call
Confident tone
XPro Phase 2 Alzheimer's trial design and confidence
INKmune prostate cancer trial
Pipeline expansion beyond Alzheimer's
Revenue
$28,000*
▼ 71.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Inmune Bio, Inc. Q3 FY2023 Earnings Call
Revenue
$43,000
▼ 56.1% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Inmune Bio, Inc. Q2 FY2023 Earnings Call
Revenue
$46,000
▲ 187.5% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Inmune Bio, Inc. Q1 FY2023 Earnings Call
Revenue
$38,000
▼ 76.7% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-03
Inmune Bio, Inc. Q4 FY2022 Earnings Call
Revenue
$97,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Inmune Bio, Inc. Q3 FY2022 Earnings Call
Revenue
$98,000
▲ 600% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Inmune Bio, Inc. Q2 FY2022 Earnings Call
Revenue
$16,000
Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Inmune Bio, Inc. Q1 FY2022 Earnings Call
Revenue
$163,000
▲ 3975% YoY Diluted EPS
$-0.39
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-04
Inmune Bio, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Inmune Bio, Inc. Q3 FY2021 Earnings Call
Revenue
$14,000
Diluted EPS
$-0.55
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Inmune Bio, Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Inmune Bio, Inc. Q1 FY2021 Earnings Call
Revenue
$4,000
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-05
Inmune Bio, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Inmune Bio, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Inmune Bio, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Inmune Bio, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Inmune Bio, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
1711754
CUSIP
45782T105
13F (30d)
78 filings
78 filers
Visit website
Investor relations